Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms
Top Cited Papers
- 28 February 2019
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 133 (9), 906-918
- https://doi.org/10.1182/blood-2018-11-882993
Abstract
Thrombosis with associated inflammation (thromboinflammation) occurs commonly in a broad range of human disorders. It is well recognized clinically in the context of superficial thrombophlebitis (thrombosis and inflammation of superficial veins), however it is more dangerous when it develops in the microvasculature of injured tissues and organs. Microvascular thrombosis with associated inflammation is well recognized in the context of sepsis and ischemia-reperfusion injury, however it also occurs in organ transplant rejection, major trauma, severe burns, the antiphospholipid syndrome, preeclampsia, sickle cell disease and biomaterial-induced thromboinflammation. Central to thromboinflammation is the loss of the normal antithrombotic and anti-inflammatory functions of endothelial cells, leading to dysregulation of coagulation, complement, platelet activation and leukocyte recruitment in the microvasculature. α-thrombin plays a critical role in co-ordinating thrombotic and inflammatory responses and has long been considered an attractive therapeutic target to reduce thromboinflammatory complications. This review focuses on the role of basic aspects of coagulation and α-thrombin in promoting thromboinflammatory responses, and discusses insights gained from clinical trials on the effects of various inhibitors of coagulation on thromboinflammatory disorders. Studies in sepsis patients have been particularly informative, in that despite using anticoagulant approaches with different pharmacological profiles, which act at distinct points in the coagulation cascade, bleeding complications continue to undermine clinical benefit. Future advances may require the development of therapeutics with primary anti-inflammatory and cytoprotective properties, that have less impact on hemostasis. This may be possible with the growing recognition that components of blood coagulation and platelets have prothrombotic and proinflammatory functions independent of their hemostatic effects.Keywords
This publication has 130 references indexed in Scilit:
- Platelets Induce Apoptosis during Sepsis in a Contact-Dependent Manner That Is Inhibited by GPIIb/IIIa BlockadePLOS ONE, 2012
- Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsisBlood, 2012
- Polyphosphate is a cofactor for the activation of factor XI by thrombinBlood, 2011
- Activation of factor XI by products of prothrombin activationBlood, 2011
- Platelets: versatile modifiers of innate and adaptive immune responses to transplantsCurrent Opinion in Organ Transplantation, 2011
- Properties of Procoagulant PlateletsArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic miceBlood, 2010
- Deficiency of PAR4 Attenuates Cerebral Ischemia/Reperfusion Injury in MiceJournal of Cerebral Blood Flow & Metabolism, 2010
- TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humansJCI Insight, 2009
- Neuroprotective activities of activated protein C mutant with reduced anticoagulant activityEuropean Journal of Neuroscience, 2009